Triple Fixed-dose combination of Dapagliflozin, Sitagliptin, and Metformin for People with Type 2 Diabetes in Indian Settings
Abstract
Objective: This study assessed the bioequivalence of a fixed-dose combination (FDC) therapy containing extended-release Metformin (Metformin XR), Dapagliflozin, and Sitagliptin for treating type 2 diabetes (T2D). The objective was to compare the absorption rate and extent of the FDC with two reference products: Sitagliptin 100mg tablets (R1) and a combination of Dapagliflozin 10mg plus Metformin 1000mg extended-release tablets (R2) in healthy adult males under fed conditions.
Methods: An open-label, randomized, cross-over study was conducted with 24 healthy male participants. Each participant received a single dose of the test FDC and the reference products, with blood samples collected over 72 hours to evaluate pharmacokinetic parameters (Cmax, AUC0-t, AUC0-inf, Tmax, Kel, AUC_% Extrap_obs, and t1/2). Bioequivalence was determined based on the 90% confidence intervals (CIs) of the geometric mean ratios for AUC0-t and Cmax, within a predefined range of 80.00%-125.00%. Safety and tolerability were also assessed.
Results: Pharmacokinetic analysis was performed on 22 subjects. The geometric mean ratios for the FDC compared to the reference products were within the predefined bioequivalence range, indicating that the absorption profiles of the FDC and the reference products were similar. The mean plasma concentration-time curves for Dapagliflozin, Sitagliptin, and Metformin XR were almost identical between the FDC and reference products, demonstrating consistent drug release and absorption. No significant differences were observed in Tmax, t1/2, or other pharmacokinetic parameters, further supporting bioequivalence. Additionally, the FDC was well-tolerated, with no serious adverse events reported, and all subjects completed the study without complications.
Conclusion: The study confirmed that the FDC of Dapagliflozin, Sitagliptin, and Metformin XR is bioequivalent to the reference products in healthy adult males under fed conditions. This bioequivalence supports the use of the FDC as an effective treatment option to improve glycemic control in adults with T2D, particularly in the Indian context, promoting the benefits of combined therapy in managing diabetes.
Keywords: Bioequivalence, Fixed-dose combination (FDC), Type 2 diabetes (T2D), Pharmacokinetics, Dapagliflozin, Metformin XR, Sitagliptin
Keywords:
Type 2 Diabetes, Dapaglilfozin, Sitagliptin, Metformin, Fixed dose combination, PharmacokineticsDOI
https://doi.org/10.22270/jddt.v14i9.6692References
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2022; 45:2753-2786. https://doi.org/10.2337/dci22-0034 PMid:36148880 PMCid:PMC10008140
Doyle-Delgado K, Chamberlain JJ, Shubrook JH, Skolnik N, Trujillo J. Pharmacologic approaches to glycemic treatment of type 2 diabetes: synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline. Ann Intern Med. 2020; 173:813-821. https://doi.org/10.7326/M20-2470 PMid:32866414
Chang M, Liu X, Cui D, Liang D, LaCreta F, Griffen SC, et al. Bioequivalence, food effect, and steady-state assessment of Dapagliflozin/Metformin extended-release fixed-dose combination tablets relative to single-component Dapagliflozin and Metformin extended-release tablets in healthy subjects. Clin Ther. 2015; 37:1517-1528. https://doi.org/10.1016/j.clinthera.2015.05.004 PMid:26048185
Turner RC, Cull CA, Frighi V, Holman RR UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, Metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49) JAMA. 1999; 281:2005-2012. https://doi.org/10.1001/jama.281.21.2005 PMid:10359389
Kalra S, Das AK, Priya G, Ghosh S, Mehrotra RN, Das S, et al. Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panel. J Family Med Prim Care. 2020; 9:5450-5457. https://doi.org/10.4103/jfmpc.jfmpc_843_20 PMid:33532378 PMCid:PMC7842427
List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with Dapagliflozin in type 2 diabetes. Diabetes Care. 2009; 32:650-657. https://doi.org/10.2337/dc08-1863 PMid:19114612 PMCid:PMC2660449
Pancholia AK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Indian Heart J. 2018; 70:915-921. https://doi.org/10.1016/j.ihj.2018.08.022 PMid:30580866 PMCid:PMC6306386
Khomitskaya Y, Tikhonova N, Gudkov K, Erofeeva S, Holmes V, Dayton B, et al. Bioequivalence of Dapagliflozin/Metformin extended-release fixed-combination drug product and single-component Dapagliflozin and Metformin extended-release tablets in healthy russian subjects. Clin Ther. 2018; 40:550-561.e3. https://doi.org/10.1016/j.clinthera.2018.02.006 PMid:29548719
Tang W, Engman H, Zhu Y, Dayton B, Boulton DW. Bioequivalence and food effect of Dapagliflozin/saxagliptin/Metformin extended-release fixed-combination drug products compared with coadministration of the individual components in healthy subjects. Clin Ther. 2019; 41:1545-1563. https://doi.org/10.1016/j.clinthera.2019.05.015 PMid:31266654
Kasichayanula S, Liu X, Shyu WC, Zhang W, Pfister M, Griffen SC, et al. Lack of pharmacokinetic interaction between Dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and Metformin, pioglitazone, glimepiride or Sitagliptin in healthy subjects. Diabetes Obes Metab. 2011; 13:47-54. https://doi.org/10.1111/j.1463-1326.2010.01314.x PMid:21114603
Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, Metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012; 66:446-456. https://doi.org/10.1111/j.1742-1241.2012.02911.x PMid:22413962
Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of Dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with Metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 375:2223-2233. https://doi.org/10.1016/S0140-6736(10)60407-2 PMid:20609968
Cheng L, Fu Q, Zhou L, Fan Y, Liu F, Fan Y, et al. Dapagliflozin, Metformin, monotherapy or both in patients with metabolic syndrome. Sci Rep. 2021; 11:24263. https://doi.org/10.1038/s41598-021-03773-z PMid:34930986 PMCid:PMC8688417
General Assembly of the World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent. 2014;81(3):14-18.
Que L, Qin W, Shi Y, et al. Pharmacokinetic comparison of sitagliptin and metformin HCl extended-release tablets versus JANUMET® XR in healthy volunteers under fasting and fed conditions. Front Pharmacol. 2023;14:1105767. Published 2023 Mar 22. https://doi.org/10.3389/fphar.2023.1105767 PMid:37033652 PMCid:PMC10073488
Published
Abstract Display: 1267 
PDF Downloads: 1101 PDF Downloads: 139 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.